Small-cap biotech penny stocks face cash-burn — What Could Drive the Next Move?

Small-cap biotech penny stocks face cash-burn — What Could Drive the Next Move? →

Highlights Small-cap biotech penny stocks face cash-burn and capital-raise pressures; successful clinical trials unlock multiples-of-current valuation potential Poolbeg Pharma focused on cancer immunotherapy; sector benefiting from pipeline…